Soft-tissue sarcomas are a heterogeneous group of tumors arising from connective tissue. Recently, mutations in the neurofibromin 1 (NF1) tumor suppressor gene were identified in multiple subtypes of human soft-tissue sarcomas. To study the effect of NF1 inactivation in the initiation and progression of distinct sarcoma subtypes, we have developed a novel mouse model of temporally and spatially restricted NF1-deleted sarcoma. Treatment with PD325901 delays tumor growth through decreased cyclin D1 mRNA and cell proliferation. We also examined the effects of MEK inhibition on the native tumor stroma and find that PD325901 decreases VEGFα expression in tumor cells with a corresponding decrease in microvessel density. Taken together, our results utilize a primary tumor model to demonstrate that sarcomas can be generated by loss of NF1 and Ink4a/Arf, and that these tumors are sensitive to MEK inhibition by direct effects on tumor cells and the surrounding microenvironment. These studies suggest that MEK inhibitors should be further explored as potential sarcoma therapies in patients with tumors containing NF1 deletion.
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To generate primary sarcomas, we inject adenovirus containing Cre recombinase into NF1 flox/flox ; Ink4a/Arf flox/flox mice at two distinct orthotopic sites: intramuscularly or in the sciatic nerve. The mice develop either high-grade myogenic sarcomas or MPNST-like tumors, respectively. These tumors reflect the histological properties and spectrum of sarcomas found in patients. To explore the utility of this model for preclinical studies, we performed a study of MAPK pathway inhibition with the MEK inhibitor PD325901.
Treatment with PD325901 delays tumor growth through decreased cyclin D1 mRNA and cell proliferation. We also examined the effects of MEK inhibition on the native tumor stroma and find that PD325901 decreases
VEGFα expression in tumor cells with a corresponding decrease in microvessel density. Taken together, our results utilize a primary tumor model to demonstrate that sarcomas can be generated by loss of NF1 and Ink4a/Arf, and that these tumors are sensitive to MEK inhibition by direct effects on tumor cells and the surrounding microenvironment. These studies suggest that MEK inhibitors should be further explored as potential sarcoma therapies in patients with tumors containing NF1 deletion.
INTRODUCTION
Soft-tissue sarcomas are an aggressive and heterogeneous group of tumors that arise from connective tissue, including the muscle, nerve sheath, blood vessel, fat, and fibrous tissue. These tumors are fatal in thirty percent of patients (1) , and the standard treatment of wide resection and radiation carries considerable morbidity among survivors. Recent genomic studies have identified novel mutations in a diverse spectrum of human soft tissue sarcomas that may reveal new molecular targets for therapy (2) . One of the most frequently mutated genes described is neurofibromin 1 (NF1), a tumor suppressor that functions as a negative regulator of the Ras pathway. Although the loss of NF1 is well-characterized in malignant peripheral nerve sheath tumors (MPNSTs), NF1 mutations in other soft-tissue sarcomas have only been recently identified. Using genomic sequencing and copy number analysis, NF1 mutations were identified in myxofibrosarcoma (10.5%, n = 4 /38) and pleomorphic liposarcoma (8%, n = 2/24) (3). Similar studies have identified genomic loss of the NF1 locus in 15% of pediatric embryonal rhabdomyosarcomas (n = 4/26) (4). This deletion was mutually exclusive with Ras gene mutations. The identification of novel mutations in sarcomas with complex karyotypes provides new opportunities to model human sarcomas and to investigate new therapies for this difficult to treat disease.
In addition to identifying NF1 mutations in spontaneous sarcomas in the general population, patients with Neurofibromatosis Type 1 (NF1) are at increased risk for developing aggressive soft-tissue sarcomas.
Neurofibromatosis Type 1 effects 1 in 3000 live births and is caused by germline inactivation of a single allele of the NF1 gene (5) . The most common sarcoma afflicting NF1 patients is malignant peripheral nerve sheath 3 tumor (MPNST), with a lifetime risk of 8-13% (5) . NF1 patients are also at risk for developing non-neurogenic sarcomas, including rhabdomyosarcoma (RMS) and undifferentiated pleomorphic sarcoma (UPS), with a 3-6% lifetime risk (6) (7) (8) . Most malignant NF1-deleted tumors have inactivation of either p53 or Ink4a/Arf tumor suppressor genes, with over 50% of MPNSTs expressing wild-type p53 and homozygous deletion of Ink4a/Arf (9) . Deletion of NF1 alone is not sufficient to cause high-grade sarcomas, as tissue-specific deletion of NF1
with either Krox20-Cre or Dhh-Cre results in neurofibromas (10, 11) . Similarly, deletion of either Ink4a or Arf alone is not sufficient for formation of neurofibromas or MPNSTs on an NF1 heterozygous background from either NF1 +/-; Ink4a -/-mice (12) or NF1 +/-; Arf -/-mice (13) . Additionally, we have previously reported that conditional deletion of Ink4a/Arf alone by Ad-Cre injection is insufficient for sarcoma initiation (14) . Deletion of both Ink4a and Arf in an NF1 heterozygous background (NF1 +/-; Ink4a/Arf -/) generated sporadic MPNSTs in 26% of mice (12) . The most widely-used NF1-dependent mouse sarcoma model is the NF1 +/-; p53 +/-cis mouse, which develops NF1-and p53-null sarcomas throughout the body following loss-of-heterozygosity (15, 16) . Despite the prevalence of NF1 mutations in soft-tissue sarcomas, the role of NF1 in the development of soft-tissue sarcomas, particularly in the background of wild-type p53 alleles, has not been fully explored in a primary mouse model of soft-tissue sarcoma. Therefore, we designed a study to test if deletion of both NF1 and Ink4a/Arf could generate high-grade soft-tissue sarcomas in an NF1 wild-type background.
Genetically-engineered mouse models have greatly advanced our understanding of sarcomas (14, 15, (17) (18) (19) and have served as a preclinical platform for therapies (20) (21) (22) (23) (24) (25) . However, for many models, mice develop sarcomas at multiple sites, which can make tumor detection and assessment of treatment response challenging.
Here, we developed a novel mouse model of temporally and spatially restricted NF1-deleted sarcoma to increase our understanding of NF1-mutant tumors. Using Cre-loxP technology, tumors are initiated through
Cre-mediated deletion of conditional NF1 and Ink4a/Arf floxed alleles (NF1 flox/flox ; Ink4a/Arf flox/flox ). These mice develop both high-grade myogenic sarcomas and MPNST-like tumors, based on the site of Cre injection.
These tumors reflect the histological properties and spectrum of sarcomas found in patients. Because sarcomas in this model develop in a spatially and temporally restricted manner, this model is particularly useful for testing therapeutic drug responses, and we have used this model as a preclinical platform to assess new therapies for patients with NF1-deleted sarcomas. We have identified MAPK inhibition as a promising therapy that slows the growth of primary mouse sarcomas through effects on tumor cell growth and the surrounding vasculature. Importantly, this model is able to directly assess the effects of MEK inhibition on native tumor stroma, as these primary tumors develop in immunocompetent mice with native vasculature. By demonstrating the ability of these tumors to respond to MEK inhibition, we lay a foundation for future studies using this model to test the efficacy of other drugs for NF1-deficient sarcomas in the pre-clinical setting.
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MATERIALS AND METHODS
Mouse Sarcoma Model
All mouse work was performed in accordance with Duke University Institutional Animal Care and Use
Committee approved protocols. The NF1 flox/flox mice (11) and Ink4a/Arf flox/flox mice (26) have been previously reported.
Primers sequences used to demonstrate recombination of the appropriate alleles are found in Supplemental Table 1 or have been previously reported (11) . Tumors were generated by injection of Adenovirus-expressing Cre recombinase (Ad-Cre; University of Iowa, Vector core) into the lower left leg of NF1 flox/flox ; Ink4a/Arf flox/flox compound mutant mice as previously described (14) . For sciatic nerve injections, the nerve was exposed by an incision in the surrounding muscle, followed by injection of 25 μl Ad-Cre into the nerve. Tumor volumes were calculated using the formula V = (π × L × W × H)/6, with L, W, and H representing the length, width, and height of the tumor in mm, respectively.
Histology and Immunostaining
Antibodies for immunohistochemistry included: S100 (Dako Cytomation), MyoD1 (Dako Cytomation), pERK (Cell Signaling), pS6 (Cell Signaling), Ki67 (BD Pharmagen), CD31 (BD Pharmagen), pVEGFR-2 (Cell Signaling), and MECA-32 (BD Pharmagen). All immunostaining was perfomed with citrate-based antigen retrieval, with the exception of MECA-32 and pVEGFR2, which were performed with EDTA-based retrieval.
TUNEL staining used the In Situ Cell Death Detection Kit, TMR Red (Sigma), per manufacturer's instructions.
To visualize mast cells, slides were stained with Toluidine Blue solution (0.02% Toluidine Blue in 1% NaCl, pH=2.2) for 2 minutes, followed by 2 washes in distilled water and 3 washes in 100% ethanol. To quantify
PD325901 Inhibitor Treatment
Treatment started when tumors were between 200-300 mm 3 . Mice receiving vehicle alone were treated with NMP 10% (1-methyl-2-pyrrolidone)/PEG300 90% (Fluka) orally 5 days per week. PD325901 (27) Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
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Criteria for defining treatment response includes both volumetric analysis and a delay in tumor growth kinetics.
A partial response (PR) is classified as a tumor that: 1) demonstrates a decrease in tumor volume from baseline measurements and 2) shows delayed growth kinetics (defined as requiring more than 10 days to increase in volume 150%). For waterfall plot analyses, percent maximal change is reported as the greatest percent loss in tumor volume from baseline for tumors responding to treatment. Tumors that did not respond to treatment are shown as greatest percent gain in tumor volume from baseline over the course of the treatment. In this presentation of the data, change in tumor volume is capped at +100%.
Statistical Analysis
Graphs and statistics were performed in Graph Pad 4.0. A non-parametric student's t-test was performed to determine differences between treatment groups. A p-value of <0.05 was considered statistically significant.
In vitro studies
The mouse sarcoma cell lines 1863 and 3017 were derived from primary sarcomas in NF1 
Western blot analysis
1863 cells were treated with 50 nM PD325901 for either 1 or 4 hours prior to harvest. Cells were washed once with cold PBS (Sigma) and lysed for 10 minutes on ice with RIPA buffer (Sigma), supplemented with phosphatase inhibitors (Sigma, P5726 and P0044). Protein concentration was performed with BCA Protein
Concentration Assay (Thermo Scientific). MiniProtean TGX gels (BioRad) were transferred to PVDF by wet transfer.
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Quantitative RT-PCR RNA was isolated from tumors and cells by TRIZOL. cDNA synthesis was performed with iScript (BioRad).
Quantitative RT-PCR was performed on an iQ5 instrument (BioRad) using the delta-delta Ct method. Primer sequences can be found in Supplementary Table 2 .
RESULTS
Generating inducible NF1-deleted sarcomas in the mouse
As NF1 mutations have been recently detected in a variety of human soft-tissue sarcoma subtypes (3, 4), we sought to determine if loss of NF1 and the tumor suppressor Ink4a/Arf was sufficient to generate soft-tissue sarcomas in a p53-and NF1-wild type background. Furthermore, we wished to generate an inducible mouse model of NF1-deleted sarcoma that could reflect the diverse spectrum of NF1-associated sarcomas found in patients. Therefore, we generated mice with conditional mutations in both NF1 and Ink4a/Arf ( Histopathological analysis determined that these tumors reflect the histological properties and spectrum of disease seen in human NF1-associated sarcomas ( Figure 1D ). Sciatic nerve injections result in tumors with a fascicular pattern of tightly packed spindle cells surrounding the nerve (Supplemental Figure 2A ). As seen in other mouse models of nerve sheath tumors (10, 22) , these sarcomas demonstrate focal positivity for S100ß, but do not show nuclear expression for the myogenic-lineage marker MyoD1. In contrast, IM injections generate a 7 spectrum of high-grade spindle cell sarcomas, including rhabdomyosarcoma (RMS, n=5/10) and Undifferentiated Pleomorphic Sarcoma (UPS, n=5/10), the most common and aggressive form of soft tissue sarcoma in adults (Supplemental Figure 2B ). Both RMS and UPS occur in patients with neurofibromatosis type 1 (6-8), and NF1 mutations have been identified in these sarcoma subtypes. Similar to other mouse models of myogenic sarcoma and their human tumor subtypes (14, 28) , the IM tumors express the myogenic marker
MyoD1, but do not stain focally for S100 ß. NF1-associated sarcomas in patients have active RAS/MAPK/ERK and PI3K/AKT/mTOR signaling (29, 30) . Therefore, we hypothesized that the MEK target ERK and the mTOR target S6 would be phosphorylated in these primary NF1-deleted mouse sarcomas. Immunohistochemical analysis for pERK and pS6 reveals that MAPK and mTOR pathways are active in both SN and IM primary tumors from NF1 flox/flox ; Ink4a flox/flox mice ( Figure 1D ). Taken together, these data suggest that this mouse model reflects the spectrum of NF1-deleted sarcomas found in the human population, and that distinct sarcoma subtypes can be generated from the same mouse strain by Ad-Cre injection into different orthotopic sites. Figure   2B ). In both tumor types, average CD31+ microvessel density is similar, although vessel distribution between individual tumors varies considerably ( Figure 2C ). Taken together, these data suggest that while this mouse model consistently develops tumors with distinct histological properties, there is individual tumor-to-tumor heterogeneity in phenotypes such as mast cell infiltration, proliferation and vascularity, with intramuscular tumors showing higher Ki67 levels. As human NF1-associated sarcomas also display heterogeneity by histological analysis (7), we hypothesize that the heterogeneity observed in this mouse model will be useful for testing therapies directed against NF1-deleted sarcoma in the preclinical setting.
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Efficacy of MEK inhibition in NF1-deleted sarcomas
The identification of NF1 mutations in myogenic sarcoma (3, 4) Figure 3C ). Among the tumors that responded to treatment, the degree of response varied, which has been observed in other primary sarcoma models (20, 32) .
The range of treatment response for individual tumors during PD325901 exposure is similar to the individual tumor-to-tumor heterogeneity observed in Ki67 and CD31 staining (Figure 2 ). Immunohistochemical analysis reveals that tumors responding to treatment have lower levels of MAPK and mTOR signaling compared to vehicle-treated tumors, as determined by a decrease in pERK and pS6 levels ( Figure 3D ). In contrast, tumors that did not respond to treatment showed hyper-elevated levels of both pERK and pS6, suggesting that these tumors escaped from treatment by alternative activation of these pathways. These results show that MEK inhibition slows growth of NF1-deleted rhabdomyosarcoma and undifferentiated pleomorphic sarcoma, as the 9 histologies for each of these high-grade sarcoma subtype were evenly distributed between vehicle treated, responders, and non-responding tumors.
To determine the mechanism of tumor control produced by MEK inhibition, we examined the Ki67 index between vehicle and PD325901-treated tumors ( Figure 4A ). Tumors that responded to treatment show a decrease in proliferative index determined by Ki67 staining (p<0.05). Of note, the two non-responding (NR)
tumors have Ki67 levels similar to vehicle-treated tumors, despite exposure to the inhibitor. TUNEL staining demonstrates that PD325901 treatment did not significantly increase apoptosis, although non-responders paradoxically show a high number of TUNEL-positive cells ( Figure 4B ). Tumors that responded to PD325901 treatment exhibit a significant decrease in levels of cyclin D1 mRNA (p<0.05), supporting previous reports that suggest inhibition of the cell cycle contributes to the decrease in tumor cell proliferation observed with this agent (33) ( Figure 4C ). Similar downregulation of cyclin D1 mRNA is observed during in vitro exposure of NF1-deleted sarcoma cells to PD325901, demonstrating that the cell cycle effects are cell autonomous ( Figure   4D and Supplemental Figure 5 ). Taken together, these data suggest that PD325901 inhibits NF1-deleted sarcomas through cytostatic, but not cytotoxic, mechanisms. Very recently, others have used PD325901 to treat neurofibromatosis-associated diseases (34, 35) , and treatment of a primary neurofibroma model with PD325901 resulted in decreased proliferation as measured by Ki67 staining, but not an increase in apoptosis (36) .
However, it is important to note that both the cellular context of the treated cancer and the specific target that is inhibited determine the effect of an agent to work in cytotoxic or cytostatic contexts.
MEK inhibition alters the tumor microenvironment
The effect of targeted therapies on the surrounding tumor stroma is an important component of therapeutic efficacy. Recently, the MEK inhibitor PD325901 was shown to inhibit angiogenesis and VEGF signaling in xenografted tumor models of RCC and lung cancer (37, 38) . While these xenograft models provide valuable information about tumor response, we sought to extend these findings to our NF1-deleted sarcoma In contrast, MEK inhibition results in a significant decrease in CD31+ microvessel density (p=0.010, Figure 5B ). As similar effects on the endothelium have been observed with MEK inhibition in a primary model of neurofibroma (36), we further characterized the molecular reprogramming responsible for vascular changes in our primary high-grade sarcomas. To determine the changes in several angiogenic markers that may correlate with the decreased endothelial cell content in the tumors, we performed quantitative RT-PCR on vehicle-treated and PD325901-treated tumors. Expression of the mRNA for the VEGFα isoforms VEGF 120 and VEGF 165 was decreased in treated tumors, while message levels for the VEGF 188 isoform were not significantly altered ( Figure 5C ). Levels of Angiopoetin 2 (Angpt 2) mRNA were lower in treated tumors, but levels of other endothelial cell markers were unaffected, including Angiopoetin 1. Additionally, mRNA levels of other angiogenesis-related genes were unchanged, including Tie2, VegfR-1, VegfR-2, Pdgf-ß, PdgfR, Neuropilin, Hif1α, and Hif2α (Supplemental Figure 6 ). Angiopoeitin 2 can have pro-angiogenic properties when combined with increased VEGFα expression (43) . Therefore, decreased levels of Angpt2, VEGF 120, and VEGF 165 mRNA suggest a potential mechanism for the decreased vascularity seen with PD325901 exposure. To determine if the change in angiogenic genes following PD325901 treatment was primarily through action on the tumor cells or on tumor stroma, we treated NF1-deficient sarcoma cells with PD325901.
Following a 4 hour treatment with the inhibitor, both cell lines exhibited decreased levels of VEGF 120 and VEGF 165 mRNA, similar to the primary tumors ( Figure 5C ). However, levels of Angiopoeitin 2 remain unchanged in the PD325901-treated tumor cells. These data suggest that some of the decrease in VEGF mRNA levels following PD325901 treatment occurs in the sarcoma cells, but the changes in Angiopoeitin 2 levels observed in intact tumors reflect changes in the surrounding tumor stroma, perhaps in response to altered VEGF levels in the tumor cells (44) .
To determine if the decreased levels in VEGF 120, VEGF 165, and Angiopoeitin 2 mRNA in the primary tumors correspond to decreased VEGFα signaling in vivo, we performed immunofluoresence for pVEGFR-2 in the primary tumors treated with PD325901 ( Figure 5D ). Upon VEGF ligand binding, the VEGFR-2 receptor on endothelial cells is phosporylated, activating the VEGF angiogenesis signaling cascade (45) . In vehicle-treated tumors, pVEGFR-2 foci are abundant and colocalize with endothelial cells, visualized by MECA-32 staining. In contrast, PD325901-treated tumors show marked decrease in pVEGFR-2 foci, along with decay of endothelial cell architecture. These data suggest that in addition to decreasing proliferation of tumor cells, MEK inhibition has important effects on the surrounding tumor microenvironment by blocking 11 angiogenesis and decreasing tumor microvessel density. Taken together, these preclinical data suggest that the MEK inhibitor PD325901 may be a useful therapy for patients with NF1-deficient sarcomas.
DISCUSSION
We have described a novel genetically engineered inducible mouse model of NF1-deficient sarcomas. This primary mouse model can be used to study the tumor biology and therapeutic response of sarcomas with NF1 mutation. Using temporally and spatially controlled conditional gene deletion, we have determined that inactivation of NF1 and Ink4a/Arf in the tumor cells is sufficient to initiate both myogenic and MPNST-like sarcomas in mice with a wild-type stroma. High-grade myogenic sarcomas develop after intramuscular injection of adenovirus expressing Cre recombinase, and MPNST-like sarcomas develop after sciatic nerve injection. Histopathological analysis shows the spectrum of sarcomas that develop in this model are similar to sarcomas with NF1 deletion in the patient population. By initiating sarcomas through deletion of NF1 and Ink4a/Arf, these mice model the ~50% of NF1-deleted sarcomas with wild-type p53 and complement the existing models of p53-deleted NF1 mutant sarcomas for therapeutic studies (21). In this model, tumor growth is delayed by the MEK inhibitor PD325901, which is accompanied by a decrease in tumor cell proliferation but does not increase cellular apoptosis. Importantly, in this model tumors develop within their native microenvironment, facilitating the study of stromal contribution to therapeutic response, which may be more challenging in cell transplant or xenograft studies. PD325901 treatment decreases microvessel density, at least partially through a decrease in expression of proangiogenic genes, such as VEGF 120, VEGF 165 and Angiopoeitin 2. Therefore, this study demonstrates the ability of this system to model NF1-deleted sarcomas and shows its utility in characterizing targeted therapies for NF1-deficient sarcomas. Several recent studies have also reported encouraging results using MEK inhibition to treat other neurofibromin-deficient disorders in mice (34) (35) (36) .
To our knowledge, this is the first study to examine the biology of NF1-deleted high-grade myogenic sarcomas in genetically engineered mouse models, despite the prevalence of these tumors in the general population and in NF1 patients. Histological analysis shows that neither tumor location nor sarcoma subtype influences the average level of mast cell infiltration or the extent of vascularization. However, these properties are fairly heterogeneous between individual tumors, despite the fact that they all have identical initiating mutations and represent similar sarcoma subtypes. We observed a difference in Ki67 proliferative index between IM and SN subtypes, although individual tumors display a broad range of proliferative capacity within each group. This heterogeneity is a salient feature of primary tumor systems (46, 47) 
Indeed, the heterogeneity observed across primary tumors make them excellent models for examining differing tumor responses to therapy, and this model facilitated examination of tumors that were resistant to PD325901 treatment. Alternatively, these results can be viewed from the perspective that tumors may have sufficient phenotypic variation to account for the failure of treatment in non-responders. Although this diversity of response could be viewed as a limitation, we view it as a strength of the model. Although we are not able to determine if these tumors possessed a primary resistance to MEK inhibition or acquired resistance rapidly following the initial treatment, examining tumors that did not respond to PD325901 provides potential mechanisms to circumvent MEK inhibition. First, the resistant tumors have hyper-elevated Ki67 staining, suggesting they were able to grow through the treatment with increased cellular proliferation-even when accompanied by increased cellular apoptosis-resulting in a net gain in tumor growth. Alternatively, the increased apoptotic rate in non-responding tumors may be a reflection of a relatively low apoptotic rate of the responding tumors at this time point assayed. It is conceivable tumors that initially responded to therapies have elevated apoptosis during tumor response but have decreased apoptosis during tumor progression. Secondly, although all six tumors that responded to treatment showed low pERK and pS6 levels, the two tumors that did not respond to PD325901 treatment showed high levels of pERK and pS6, even above levels observed in vehicle-treated tumors. Thus, treatment may have been ineffective due to re-activation of these pathways.
These results imply that blocking mTOR in addition to ERK would be a promising therapeutic strategy for future studies. Indeed, others have demonstrated that mTOR inhibition is effective in slowing growth of NF1-deficient MPNSTs in mouse models (21, 25, 48) . However, we recognize that it can be challenging to define therapeutic windows for combination treatment of molecularly-targeted inhibitors in clinical trials. For example, recent reports have demonstrated that combination of the MEK inhibitor selumetinib with the AKT inhibitor MK-2206 results in increased toxicity when used at single-agent doses (49). Finally, the effect of PD325901 on the tumor stroma of non-responders was not well-defined, as changes in the levels of mast cells and microvessel density were varied. Although future studies will be needed to fully explore the mechanisms of resistance discussed here, this study demonstrates the utility of this mouse model to study the diversity of therapeutic responses found in NF1-deleted myogenic sarcoma.
This study examined the effects of MEK inhibition on the tumor cells and native surrounding microenvironment in a primary tumor model. Our results support a model in which PD325901 targets both the tumor cell itself and results in secondary effects on the tumor vasculature. Following MEK inhibition, the 13 sarcoma cell decreases both cyclin D1 and VEGFα mRNA levels. Lower cyclin D1 mRNA levels decrease cell proliferation, as demonstrated by lower Ki67 levels. In parallel, lower VEGFα mRNA levels prevent activation of pVEGFR-2 on surrounding endothelial cells, ultimately lowering Angiopoeitin 2 mRNA levels in the vasculature. Together with decreased VEGFα, this results in decreased microvessel density. This model is consistent with data from previous in vitro and xenograft studies using MEK inhibitors in other tumors types (33, 37, 38) . Alternatively, it is also possible that PD325901 could have direct effects on the tumor endothelial cells, which has been reported in vitro (50, 51).
In summary, we have developed a novel mouse model of NF1 deleted sarcoma with wild-type p53 status. The tumor spectrum observed after IM and SN injections of Ad-Cre is similar to the clinical spectrum of NF1-deleted sarcoma. We have used this model to assess the efficacy of PD325901 and to investigate its mechanism of action in a primary tumor model. We anticipate that this model will be useful as a pre-clinical platform for other novel therapies and for further studies to examine the interplay between the microenvironment and NF1-deficent sarcoma cells during therapeutic response. Cell Lines Cell lines
